Onco-Innovations Advances AI and Quantum Drug Discovery with Kuano Collaboration to Accelerate PNKP Inhibitor Technology Development

Executive Summary

• Onco‑Innovations Limited announced a pilot collaboration with Kuano Ltd. to apply quantum‑ready analytics and AI‑driven modelling to its PNKP inhibitor platform (A83B4C63).
• The partnership aims to generate detailed structural binding models, mechanistic hypotheses, and optimized analogs that could accelerate pre‑clinical validation of next‑generation oncology therapeutics.
• The pilot runs through Q4 2025 and is expected to produce validated outputs that will feed into subsequent QSAR modelling, toxicity mapping, and generative compound design efforts.

Key Details

• Collaboration Scope: Kuano will deploy its quantum molecular‑modelling platform to analyze the interaction of A83B4C63 with the PNKP target, providing binding poses, conformational changes, and inhibition mechanisms.
• Technology Focus: Integration of Kuano’s quantum‑level analytics with Onco’s AI‑enabled discovery environment to streamline modelling → validation → synthesis workflow for PNKP‑targeting compounds.
• Pilot Timeline: Commences immediately; runs through the fourth quarter of 2025.
• Deliverables Expected:
• Validated platform outputs (e.g., high‑resolution structural binding models).
• Mechanistic hypotheses to guide structure optimisation.
• Candidate generation for next‑generation therapeutics within the PNKP inhibitor pipeline.
• Future Work: Results will inform follow‑on initiatives including quantum‑ready QSAR modelling, toxicity mapping, and generative compound design across the broader PNKP technology portfolio.
• Executive Statements:
• Vid Stojevic, CEO & Co‑Founder of Kuano: Emphasised the use of quantum precision to accelerate oncology drug design.
• Thomas O’Shaughnessy, CEO of Onco‑Innovations: Highlighted the strategic importance of integrating advanced computational science to lead next‑generation oncology development.

Notable Quotes

• “We are thrilled to apply Kuano's quantum-enabled platform to a challenging oncology target… we aim to bring new insights to PNKP inhibition and help accelerate the design of next‑generation therapeutics.” – Vid Stojevic, CEO & Co‑Founder, Kuano Ltd.
• “Our work with Kuano reflects a clear strategic direction for Onco‑Innovations to lead in next‑generation oncology… this pilot represents an important step toward realizing the full potential of our PNKP Inhibitor Technology.” – Thomas O’Shaughnessy, CEO, Onco‑Innovations Limited

Materiality Assessment: Material – Positive (the collaboration introduces a potentially significant advancement in drug discovery that could materially affect future product pipelines and valuation).